Prevalence of Erectile Dysfunction in Men Screened for Prostate Cancer

Bianco, Fernando J.; McHone, Benjamin; Wagner, Kristopher; King, Andre; Burgess, Jacqueline; Patierno, Steve; Jarrett, Thomas W.

doi:10.1016/j.urology.2008.03.036

Cited by 8 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7,13,15 In our series all interBX intervals exceeded 1 month and 75% exceeded 3 months. Population based studies in men older than 40 years 12,16,17 and PCa screening studies 18,19 showed that 26% to 50% of men self-reported mild to severe ED. In our sample analysis done on the EF scale indicated that men on active surveillance retain an average of 72% of EF.…”

Section: Discussionmentioning

confidence: 99%

The Impact of Serial Prostate Biopsies on Sexual Function in Men on Active Surveillance for Prostate Cancer

et al. 2012

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The Impact of Serial Prostate Biopsies on Sexual Function in Men on Active Surveillance for Prostate Cancer

et al. 2012

View full text Add to dashboard Cite

show abstract

“… The International Index of Erectile Function-5 (IIEF-5) or SHIM questionnaire will be used to assess erectile function [ 33 ]. The maximum score of 25 indicates maximal erectile function, while scores of 17 or lower indicate erectile dysfunction [ 34 ]. Both changes in total SHIM scores from baseline and the total SHIM score at any given time point will be reported.…”

Section: Methodsmentioning

confidence: 99%

Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial

et al. 2021

View full text Add to dashboard Cite

Background Stereotactic body radiotherapy (SBRT) is becoming increasingly used in treating localized prostate cancer (PCa), with evidence showing similar toxicity and efficacy profiles when compared with longer courses of definitive radiation. Magnetic resonance imaging (MRI)-guided radiotherapy has multiple potential advantages over standard computed tomography (CT)-guided radiotherapy, including enhanced prostate visualization (abrogating the need for fiducials and MRI fusion), enhanced identification of the urethra, the ability to track the prostate in real-time, and the capacity to perform online adaptive planning. However, it is unknown whether these potential advantages translate into improved outcomes. This phase III randomized superiority trial is designed to prospectively evaluate whether toxicity is lower after MRI-guided versus CT-guided SBRT. Methods Three hundred men with localized PCa will be randomized in a 1:1 ratio to SBRT using CT or MRI guidance. Randomization will be stratified by baseline International Prostate Symptom Score (IPSS) (≤15 or > 15) and prostate gland volume (≤50 cc or > 50 cc). Five fractions of 8 Gy will be delivered to the prostate over the course of fourteen days, with or without hormonal therapy and elective nodal radiotherapy (to a dose of 5 Gy per fraction) as per the investigator’s discretion. The primary endpoint is the incidence of physician-reported acute grade ≥ 2 genitourinary (GU) toxicity (during the first 90 days after SBRT), as assessed by the CTCAE version 4.03 scale. Secondary clinical endpoints include incidence of acute grade ≥ 2 gastrointestinal (GI) toxicity, 5-year cumulative incidences of physician-reported late grade ≥ 2 GU and GI toxicity, temporal changes in patient-reported quality of life (QOL) outcomes, 5-year biochemical recurrence-free survival and the proportion of fractions of MRI-guided SBRT in which online adaptive radiotherapy is used. Discussion The MIRAGE trial is the first randomized trial comparing MRI-guided with standard CT-guided SBRT for localized PCa. The primary hypothesis is that MRI-guided SBRT will lead to an improvement in the cumulative incidence of acute grade ≥ 2 GU toxicity when compared to CT-guided SBRT. The pragmatic superiority design focused on an acute toxicity endpoint will allow an early comparison of the two technologies. Trial registration Clinicaltrials.gov identifier: NCT04384770. Date of registration: May 12, 2020. https://clinicaltrials.gov/ct2/show/NCT04384770 Protocol version Version 2.1, Aug 28, 2020.

show abstract

“…Given the growing use of assessing sexual function using self-report measures such as the PEDT and IIEF-5 not only in the general population but also in patient cohorts, such as men suffering from prostate cancer, (Bianco, et al, 2009;Choo et al, 2010;Ong et al, 2015;Saitz et al, 2013), clinicians, especially oncologists, should know how to adopt the two useful instruments in their clinical decision making. It is therefore crucial to present specific cutoffs for the PEDT and the IIEF-5 to be able to validly diagnose sexual problems in cancer patient samples in order to foster research on the aetiological factors underlying the development of such problems in these cohorts.…”

Section: Premature Ejaculation and Erectile Dysfunction In Iranian Prostate Cancer Patientsmentioning

confidence: 99%

Premature Ejaculation and Erectile Dysfunction in Iranian Prostate Cancer Patients

Lin

Burri

Pakpour

2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: To investigate the prevalence of premature ejaculation (PE) and erectile dysfunction (ED) in a sample of patients with prostate cancer and to determine the utility of the previously suggested cutoffs of the Premature Ejaculation Diagnostic Tool (PEDT) for the diagnosis of PE and that of International Index of Erectile Function (IIEF-5) for ED. Materials and Methods: A total of 1,202 men with prostate cancer were invited from urology clinics at the universities of Iran, Tehran, Qazvin, Ahvaz, Guilan and Tabriz. Clinical characteristics were collected through medical records. PE and ED diagnoses were made by trained urologists. In addition to the clinical diagnoses, PE and ED were measured through self-report using the PEDT and the IIEF-5. Questionnaire cutoff scores were determined using receiver operating characteristic (ROC) curves and confirmed by predictive ability using logistic regression. Results: The prevalence of PE was 63.7% and that of ED was 66.2%. Prevalences of PE decreased and that of ED increased with advanced TNM stages. According to ROC, the suggested cutoff for the PEDT to diagnose a PE was ≥ 11 (sensitivity=0.988, 1-specificity=0.084, and predictive ability=0.914) and ≤ 17 for the IIEF-5 (sensitivity=0.966, 1-specificity=0.031, and predictive ability=0.967). Conclusions: Prevalence of sexual problems was high in prostate cancer patients in Iran, therefore oncologists should take into account these potential problems when deciding on treatment modalities.

show abstract

Prevalence of Erectile Dysfunction in Men Screened for Prostate Cancer

Cited by 8 publications

References 17 publications

The Impact of Serial Prostate Biopsies on Sexual Function in Men on Active Surveillance for Prostate Cancer

The Impact of Serial Prostate Biopsies on Sexual Function in Men on Active Surveillance for Prostate Cancer

Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial

Premature Ejaculation and Erectile Dysfunction in Iranian Prostate Cancer Patients

Contact Info

Product

Resources

About